In situ dsDNA-bevacizumab anticancer monoclonal antibody interaction electrochemical evaluation

Luciana I N Tomé; Nuno V Marques; Victor C Diculescu; Ana Maria Oliveira-Brett

doi:10.1016/j.aca.2015.09.049

In situ dsDNA-bevacizumab anticancer monoclonal antibody interaction electrochemical evaluation

Anal Chim Acta. 2015 Oct 22:898:28-33. doi: 10.1016/j.aca.2015.09.049. Epub 2015 Oct 8.

Authors

Luciana I N Tomé¹, Nuno V Marques², Victor C Diculescu¹, Ana Maria Oliveira-Brett³

Affiliations

¹ Chemistry Department, Faculty of Sciences and Technology, University of Coimbra, 3004-535, Coimbra, Portugal.
² Serviços Farmacêuticos, Centro Hospitalar e Universitário de Coimbra, EPE, 3000-075 Coimbra, Portugal.
³ Chemistry Department, Faculty of Sciences and Technology, University of Coimbra, 3004-535, Coimbra, Portugal. Electronic address: brett@ci.uc.pt.

PMID: 26526907
DOI: 10.1016/j.aca.2015.09.049

Abstract

The interaction of the anticancer monoclonal antibody bevacizumab (BEVA) with double-stranded DNA (dsDNA) was studied by voltammetry and gel-electrophoresis in incubated samples and using the dsDNA-electrochemical biosensor. The voltammetric results revealed a decrease and disappearance of the dsDNA oxidation peaks with increasing incubation time, showing that BEVA binds to the dsDNA but no DNA oxidative damage was detected electrochemically. Non denaturing agarose gel-electrophoresis experiments were in agreement with the voltammetric results showing the formation of compact BEVA-dsDNA adduct. The dsDNA-electrochemical biosensor in incubated solutions showed that BEVA also undergoes structural modification upon binding dsDNA, and BEVA electroactive amino acid residues oxidation peaks were detected.

Keywords: Bevacizumab; DNA damage; Glassy carbon; Interaction; Monoclonal antibody; Voltammetry; dsDNA-electrochemical biosensor.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Bevacizumab / immunology*
DNA / immunology*
Electrochemical Techniques / methods*

Substances

Bevacizumab
DNA